Document:

<PAGE>   1
                                                                    Exhibit 10.3

                          LICENSE AND SUPPLY AGREEMENT

         This License and Supply Agreement (the "Agreement"), effective as of
April 5, 1999 (the "Effective Date"), is made by and between Molecular Probes,
Inc., an Oregon corporation, ("MPI") and Cellomics(TM), Inc., a Delaware
corporation ("CI").

                                   BACKGROUND

         A.       CI has developed a cell based screening system for the
                  analysis of cellular biochemical and molecular parameters
                  through combinatorial cell biology; and

         B.       MPI has expertise in the development and manufacture of
                  certain proprietary and non-proprietary fluorescence based
                  reagents; and

         C.       CI desires to obtain from MPI and MPI desires to grant CI
                  certain licenses to use MPI's proprietary fluorescence based
                  reagents; and

         D.       The parties desire that CI purchase and MPI supply certain
                  proprietary and non-proprietary products on the terms and
                  conditions set forth below.

NOW, THEREFORE, for and in consideration of the mutual covenants and promises
herein contained, the parties hereto agree as follows:

                                    ARTICLE 1
                                   DEFINITIONS

         1.1 "CI Specifications" shall mean collectively (i) the quality control
standards, as amended from time to time, that materials supplied to CI must meet
for use under this Agreement; and (ii) the packaging protocols required by CI,
as amended from time to time, for materials supplied for use under this
Agreement.

         1.2 "Confidential Information" shall have the meaning as set forth in
Section 8.1 below.

         1.3 "Custom Product" shall mean a Licensed Material or a
Non-Proprietary Material that is not available from MPI as a Stock Item, but is
available by special request, e.g. to obtain a material that has the same
chemical formula as a Stock Item but has different quality control
specifications or special packaging requirements, or a material with a chemical
composition that is not offered as a Stock Item. For purposes of this Agreement,
consolidated packaging of bulk amounts of Stock Items are not Custom Products.

         1.4 "Field" shall mean   [*]  .

         1.5 "Finished Product(s)" shall mean any kit incorporating Licensed
Materials that is transferred by CI, in return for compensation, to a third
party for use in the Field, where the kit, or the Licensed Materials in such
kit, or the use thereof, is covered by a Valid Claim.

     "CONFIDENTIAL [*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT
OF 1933, AS AMENDED."

                                                                               1
<PAGE>   2

         1.6 "High Content Screening" or ("HCS") shall mean [*]  .

         1.7 "Licensed Material(s)" shall mean (i) any chemical or biochemical
composition(s), including Proprietary Material(s), that are covered by a Valid
Claim or, (ii) where the composition itself is not covered by a Valid Claim, its
use is covered by a Valid Claim and its manufacture is a trade secret of MPI.
Licensed Materials include, but are not limited to,  [*]  . Not all Licensed
Materials are Proprietary Materials  [*]  .

         1.8 "MPI Technology Package" shall mean the groupings of MPI Patents
that are designated in Exhibits A and B, and the corresponding MPI Technical
Information.

                  1.8.1 "MPI Patents" shall mean any issued patents or patent
applications that are identified as "Licensed Patents" on Exhibits A and B, as
amended from time to time, and all corresponding patents issuing from such
applications, and all reissues, renewals, re-examinations, and extensions
thereof, and any divisions or continuations (in whole or in part) thereof, and
any foreign equivalents thereof, as amended from time to time by the agreement
of the parties,  [*]  .

                  1.8.2 "MPI Technical Information" shall mean confidential
information, tangible or intangible, and materials, including but not limited
to: pharmaceutical, chemical, biological, genetic and biochemical compositions;
and technical and non-technical data and information, and/or the results of
tests, assays, methods and processes; and plans, specifications and/or other
documents containing said information and data; in each case that is possessed
by MPI as of the Effective Date or during the Term, to the extent such relates
to the manufacture of Licensed Materials, including Proprietary Materials, of a
given MPI Technology Package.

         1.9 "Net Sales" shall mean the gross amounts received by CI for the
Sale of Finished Products or Services, less the following amounts directly
chargeable to such Finished Products or

     "CONFIDENTIAL [*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT
OF 1933, AS AMENDED."

                                                                               2
<PAGE>   3

Services: (a) customary trade, quantity or cash discounts and rebates, actually
allowed and taken; (b) amounts repaid or credited to customers on account of
rejections; (c) freight and other transportation costs, including insurance
charges, and duties, tariffs, sales and excise taxes and other governmental
charges based directly on Sales, turnover or delivery of such Finished Products
or Services and actually paid or allowed by CI; and (d) amounts allowed or
credited due to returns or uncollectible amounts. Where Finished Materials or
Services are Sold to third parties for compensation other than cash, Net Sales
shall mean the cash equivalent of the fair market value of such other
compensation.

         1.10 "Non-Proprietary Materials" shall mean any non-proprietary
materials set forth on Exhibit C attached hereto produced by MPI and purchased
by CI pursuant to this Agreement.

         1.11 "Proprietary Materials" shall mean those materials set forth in
Exhibits A and B attached hereto, as amended from time to time, under the column
entitled "Proprietary Materials".

         1.12 "Sell", including any variations of the verb "to Sell" or the noun
"Sale" means to transfer to a third party in return for compensation, whether
such compensation is in the form of cash payment or in the form of a transfer of
a non-cash, tangible or intangible asset.

         1.13 "Services" shall mean any services conducted by CI in the Field
and covered by a Valid Claim.

         1.14 "Stock Item(s)" shall mean any material that is commercially
available from MPI and is identified with a specific product number on MPI's
website (www.probes.com) or in MPI's publications.

         1.15 "Ultra High-Throughput Screening" or ("UHTS") shall mean  [*]  .

         1.16 "Valid Claim" shall mean a written claim filed as part of any
unexpired patent application or issued patent within the MPI Patents that has
not been held unenforceable, unpatentable or invalid by a decision of a court or
governmental body of competent jurisdiction in a ruling that is unappealable or
unappealed within the time allowed for appeal, and that has not been rendered
unenforceable through disclaimer or otherwise, and that has not been lost
through an interference proceeding. In the event that the relevant MPI Patent is
a provisional patent application that does not include any claims, any specific
embodiment that is described in such provisional application shall be deemed to
be covered by a Valid Claim until such time as a corresponding utility
application is filed that contains one or more claims or such provisional
application expires without the filing of a corresponding utility application
that contains one or more claims, whichever is sooner.

     "CONFIDENTIAL [*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT
OF 1933, AS AMENDED."

                                                                               3

<PAGE>   4

                                    ARTICLE 2
                                    LICENSES

         2.1 Non-exclusive License to CI to Make or Have Made Licensed
Materials. Subject to the terms and conditions of this Agreement, MPI hereby
grants to CI a non-exclusive license under the MPI Technology Packages, to make
or have made Licensed Materials in accordance with the provisions of Article 5
below. CI is not authorized to Sell Licensed Materials except in Finished
Product(s) or in Services.

         2.2 Exclusive License to CI for Use with HCS. Subject to the terms and
conditions of this Agreement, and in accordance with the specific limitations of
this Section 2.2 (including the subsections below), MPI hereby grants to CI
certain worldwide, exclusive rights under each MPI Technology Package listed in
Exhibit A, for use in the Field, where such rights are exclusive solely for use
with HCS.

                  2.2.1 MPI hereby grants to CI an exclusive, world-wide,
royalty bearing license under the MPI Technology Packages to Sell or offer for
Sale Licensed Materials as part of Finished Products to third parties for use
with HCS.

                  2.2.2 MPI hereby grants to CI an exclusive, world-wide,
royalty bearing license under the MPI Technology Packages to import or export
Finished Products for use with HCS.

                  2.2.3 MPI hereby grants to CI an exclusive, world-wide,
royalty bearing license under the MPI Technology Packages to use Licensed
Materials with HCS in Services that are Sold or offered for Sale to third
parties.

                  2.2.4 In the event that CI is unable to (i) commercialize the
use of a given MPI Technology Package within three years after the Effective
Date, and (ii) generate royalties of $50,000 per year from such MPI Technology
Package within five years after the Effective Date, the exclusive license
granted to CI pursuant to this Section 2.2 shall become non-exclusive with
respect to that MPI Technology Package only, and the provisions of Sections
3.2.2 and 3.5 shall apply.

         2.3 Non-Exclusive License to CI for Use with UHTS. Subject to the terms
and conditions of this Agreement, and in accordance with the specific
limitations of this Section 2.3 (including the subsections below), MPI hereby
grants to CI certain worldwide, non-exclusive rights under each MPI Technology
Package listed in Exhibit A, for use in the Field, where such rights are solely
for use in UHTS.

                  2.3.1 MPI hereby grants to CI a non-exclusive, world-wide,
royalty bearing license under the MPI Technology Packages to Sell or offer for
Sale Licensed Materials as part of Finished Products to third parties for use
with UHTS.

                  2.3.2 MPI hereby grants to CI a non-exclusive, world-wide,
royalty bearing license under the MPI Technology Packages to import or export
Finished Products for use with UHTS.

     "CONFIDENTIAL [*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT
OF 1933, AS AMENDED."

                                                                               4
<PAGE>   5

                  2.3.3 MPI hereby grants to CI a non-exclusive, world-wide,
royalty bearing license under the MPI Technology Packages to use Licensed
Materials with UHTS in Services that are Sold or offered for Sale to third
parties.

         2.4 Right of First Refusal to Obtain an Exclusive License for Use in
HCS. MPI hereby grants to CI a right of first refusal ("Option"), commencing on
the Effective Date and expiring on the first anniversary thereafter ("Option
Period"), to obtain an exclusive, worldwide, royalty-bearing license under the
MPI Technology Packages listed in Exhibit B to make, have made, Sell, offer for
Sale, import, export or use Licensed Materials solely for use in HCS, in
accordance with the rights and limitations in Sections 2.1 and 2.2 above; and a
non-exclusive, worldwide, royalty-bearing license under the MPI Technology
Packages listed in Exhibit B to make, have made, Sell, offer for Sale, import,
export or use Licensed Materials solely for use in UHTS, in accordance with the
rights and limitations in Sections 2.1 and 2.3 above. Whether to exercise such
Option is solely at the discretion of CI, but CI must exercise its Option by
payment of the license fee, as described in Section 3.8, for the desired
additional MPI Technology Packages before the expiration of the Option Period.
Upon payment of the corresponding license fee(s) set forth in Section 3.8, the
same rights granted in Sections 2.1 through 2.3 covering the use of the MPI
Technology Packages in Exhibit A shall be extended automatically to cover the
use of the corresponding MPI Technology Package(s) in Exhibit B.

         2.5 Option to Add Subsequent MPI Technology Packages to Exhibit A and
Exhibit B. CI and MPI agree to negotiate in good faith the terms under which CI
shall, from time to time, add subsequent MPI Technology Packages to Exhibit A
and Exhibit B. In particular, CI shall have a right of first refusal for use and
Sale in the Field  [*] The parties anticipate the annual license fees for
each individual MPI Technology Package added hereunder shall approximate the
license fee (described in Section 3.8) for the addition of MPI Technology
Packages pursuant to Section 2.4 above.

         2.6 Termination of Rights Under Technology Packages. CI may terminate
its obligations to pay to MPI any Annual Minimum Royalty payments and royalties
under any particular MPI Technology Package by notifying MPI in writing of such
intent before the next Annual Minimum Royalty payment is due pursuant to Section
3.2, and concurrently terminating all activities described under Sections 2.1,
2.2 and 2.3 above, with respect to such MPI Technology Package.

         2.7 Exchange of Exclusive License for Non-Exclusive License. CI may
elect to change the exclusive license under a given MPI Technology Package
granted pursuant to Section 2.2, to a non-exclusive license under such MPI
Technology Package by notifying MPI in writing of such intent before the next
Annual Minimum Royalty payment is due pursuant to Section 3.2. In the event of
such an election by CI, the provisions of Section 3.2.2 and 3.5 shall apply.

         2.8 No Implied Licenses. Nothing herein shall be construed as granting
to either party, by implication, estoppel or otherwise, any license or other
right to any intellectual property of the other party other than those expressly
granted herein.

     "CONFIDENTIAL [*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT
OF 1933, AS AMENDED."

                                                                               5
<PAGE>   6

                                    ARTICLE 3
                           COMPENSATION AND ROYALTIES

         3.1 License Fee. In consideration of rights granted under Sections 2.1
through 2.3, and Section 2.5, CI shall pay to MPI a total license fee ("License
Fee") of $90,000 for the six MPI Technology Packages set forth on Exhibit A
hereto.

                  3.1.1 The License Fee shall be paid pursuant to the following
payment schedule:

                             [*]

                  3.1.2 From the License Fee paid to MPI pursuant to this
Section 3.1,  [*]  per MPI Technology Package shall be creditable against any
royalty payments for that MPI Technology Package that become due from the
Effective Date until April 1, 2000.

         3.2 Annual Minimum Royalty Payment. Beginning on April 1 of 2000 and
each subsequent anniversary thereof, CI shall pay to MPI an annual minimum
royalty ("Annual Minimum Royalty") for each MPI Technology Package in the
amounts described below, which Annual Minimum Royalty shall be creditable
against any royalties due on the corresponding MPI Technology Package during the
subsequent twelve month period following the previous Annual Minimum Royalty
payment:

                  3.2.1 For each MPI Technology Package under which CI wishes to
maintain exclusive rights pursuant to Section 2.2, as well as non-exclusive
rights pursuant to Sections 2.1 and 2.3, CI shall pay MPI an Annual Minimum
Royalty of  [*]  ;

                  3.2.2 For each MPI Technology Package in which CI wishes to
maintain non-exclusive rights pursuant to Sections 2.2.4 or 2.7, as well as
non-exclusive rights pursuant to Sections 2.1 and 2.3, the Annual Minimum
Royalty for that MPI Technology Package due to MPI by CI shall be reduced to
[*]  .

         3.3 Royalties on Services. Subject to the provisions of Section 3.5, CI
shall pay to MPI the following royalty rates for Services:

         3.3.1 For Services licensed under 2.2.3, a royalty of  [*]  in which
Licensed Material from any MPI Technology Package is used. If more than one
Licensed Material is simultaneously used  [*]  for such Services, whether from
the same MPI Technology Package or a different MPI Technology Package, CI would
pay an additional royalty of  [*]  for each additional Licensed Material used;
and

     "CONFIDENTIAL [*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT
OF 1933, AS AMENDED."

                                                                               6
<PAGE>   7
         3.3.2 For Services licensed under 2.3.3, a royalty of  [*]  received by
CI for Services in which any Licensed Material from any MPI Technology Package
is used for UHTS.

         3.4 Royalties on Finished Products. Subject to the provisions of
Section 3.5, CI shall pay to MPI the following royalty rates for Finished
Products:

         3.4.1 a royalty of  [*]  of Net Sales of Finished Products sold for use
with HCS; and

         3.4.2 a royalty of  [*]  of Net Sales of Finished Products sold for use
with UHTS.

         3.5 Reduced Royalties from Change in Exclusivity. In the event that
exclusive rights under a given MPI Technology Package for use with HCS become
non-exclusive rights pursuant to Section 2.2.4 or 2.7, CI shall pay to MPI, in
lieu of any other royalty payments, the following royalty rates:

         3.5.1 a royalty of  [*]  of Net Sales of Finished Products sold for use
with HCS; and

                  3.5.2 a royalty for Services utilizing HCS that shall be
negotiated in good faith.

         3.6 Additional Royalties from Manufacture of Licensed Materials. In the
event that CI shall make or have made Licensed Materials for use in Services or
Finished Products pursuant to Sections 5.1.6, 5.1.8 or 5.1.9, instead of
obtaining such Licensed Materials from MPI, then CI shall pay to MPI the
following royalty rates, in addition to the royalty rates under Sections 3.2,
3.3, 3.4 or 3.5:

         3.6.1 for Services licensed under 2.2.3, an additional royalty of  [*]
for each such Licensed Material used for HCS;

         3.6.2 for Services licensed under 2.3.3, an additional royalty of  [*]
received by CI for Services in which any Licensed Material from any MPI
Technology Package is used for UHTS;

         3.6.3 for Finished Products sold for use with HCS or UHTS and that
incorporate such Licensed Materials, an additional royalty of  [*]  of Net Sales
of such Finished Products.

         3.7 Option Fee. CI shall pay to MPI a non-refundable option fee of  [*]
for each MPI Technology Package set forth on Exhibit B ("Option Fee"), which
Option Fee shall be due upon the Effective Date and shall be fully creditable
against any subsequent license fee (as described in Section 3.8) for such MPI
Technology Package upon exercise of the Option.

         3.8 License Fee for Additional MPI Technology Packages. To exercise its
Option pursuant to Section 2.4 above, CI shall pay MPI a license fee for each
individual MPI Technology Package added hereunder that approximates  [*]  for
the first year (subject to the credit applied under Section 3.7 above), after
which time the Annual Minimum Royalty of Section 3.2 would apply.

     "CONFIDENTIAL [*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT
OF 1933, AS AMENDED."

                                                                               7
<PAGE>   8

                                    ARTICLE 4
                           PAYMENTS; BOOKS AND RECORDS

         4.1 Payment Terms and Method. Unless otherwise specified herein, all
payments hereunder shall be calculated on a quarterly basis from the Effective
Date and shall be due and payable sixty (60) days after. All dollar amounts
specified in this Agreement, and all payments made hereunder, are and shall be
made in U.S. dollars. If any payments are based on Net Sales denominated in
other than U.S. dollars, the conversion to U.S. dollars shall be the same
internal method CI uses to convert any other Sales denominations to U.S.
dollars, which internal method shall be in accordance with generally accepted
accounting principles.

         4.2 Any payments due under this Agreement which are not paid by the
date such payments are due under this Agreement shall bear interest to the
extent permitted by applicable law at the U.S. prime rate per annum quoted in
the "Money Rates" column of The Wall Street Journal (U.S., Western Edition) on
the first business day after such payment is due. This Section 4.2 shall in no
way limit any other remedies available to either party.

         4.3 Records. CI shall keep, complete, true and accurate books of
accounts and records for the purpose of determining the amounts payable pursuant
to this Agreement. Such books and records shall be kept for at least three (3)
years following the end of the calendar quarter to which they pertain. Such
records will be open for inspection at CI's principal place of business during
such three (3)-year period by an independent auditor chosen by MPI and
reasonably acceptable to CI for the purpose of verifying the amounts payable by
CI hereunder. Such inspections may be made no more than once each calendar year,
at reasonable times and on reasonable notice. The independent auditor shall be
obligated to execute a reasonable confidentiality agreement prior to commencing
any such inspection. Inspections conducted under this Section 4.3 shall be at
the expense of MPI, unless a variation or error producing an underpayment in
amounts payable exceeding ten percent (10%) of the amount paid for the period
covered by the inspection is established in the course of any such inspection,
whereupon all costs relating to the inspection for such period and any unpaid
amounts that are discovered shall be paid by CI, together with interest on such
unpaid amounts at the rate set forth in Section 4.2 above. The parties will
endeavor to minimize disruption of CI's normal business activities to the extent
reasonably practicable.

                                    ARTICLE 5
                             MANUFACTURE AND SUPPLY

         5.1 Exclusive Supplier of Licensed Materials. Except as expressly
provided in Sections 5.1.6, 5.1.8 or 5.1.9, MPI shall be the exclusive supplier
of all Licensed Materials.

                  5.1.1 Licensed Materials that are available from MPI as Stock
Items shall be manufactured to conform to MPI's internal specifications for
research grade reagents and packaged according MPI's internal packaging
protocols.

                  5.1.2 In the event that CI believes that such Stock Items do
not meet CI Specifications (including, e.g. where CI desires a chemical
composition that is not available as a Stock Item) CI shall notify MPI of such
CI Specifications. If such Licensed Materials are dye

                                                                               8
<PAGE>   9

conjugates of biomolecules, and the biomolecule is the basis for such Licensed
Materials not meeting CI Specifications (e.g. because CI desires a biomolecule
of a different class, or a different purity, etc.), then CI shall also identify
the nature of the desired biomolecule.

                  5.1.3 If CI desires to keep the identity of the desired
Licensed Material secret, CI shall indicate the confidential nature of its
communication, and MPI shall indicate the terms and conditions, if any, under
which such Licensed Material could be made available exclusively to CI as a
Custom Product and such Custom Product would not be made a Stock Item.

                  5.1.4 Within fifteen (15) days of CI's notification that
original Stock Items do not meet CI Specifications, MPI shall notify CI whether
or not MPI waives its right under Section 5.1 to exclusively manufacture a
Licensed Material that meets such CI Specifications.

                  5.1.5 If MPI does not waive its exclusive manufacturing right
for such specified Licensed Material at issue, MPI shall (concurrently with
MPI's notification to CI pursuant to Section 5.1.4) provide CI with a firm
quotation (including both price and delivery schedule) for such Licensed
Materials meeting such CI Specifications, and addressing all concerns under
Sections 5.1.3 and 5.2.5.

                  5.1.6 If the Licensed Material is not a Proprietary Material
and CI elects not to accept MPI's quotation, CI may make or have made the
Licensed Material for use in accordance with Article 2, subject to the
provisions of Sections 3.6, 6.2 and 6.5.

                  5.1.7 In the event that such Stock Items that do not meet CI
Specifications pursuant to this Section 5.1 are Proprietary Materials, CI may
request that such Proprietary Materials be supplied as a Custom Product, which
will be supplied at prices to be negotiated in good faith, and taking into
account all concerns under Sections 5.1.3 and 5.2.5.

                  5.1.8 In the event that MPI waives its rights to exclusively
manufacture a specific Licensed Material, CI shall have the right to make or
have made such Licensed Material for use in accordance with Article 2, subject
to the provisions of Sections 3.6, 6.2 and 6.5.

                  5.1.9 Notwithstanding the provisions of Section 11.2, CI shall
have the right to make or have made a given Proprietary Material, subject to the
provisions of Section 3.6, 6.2 and 6.5 in the event that:

                           (i) MPI fails to deliver such Proprietary Material as
stated on any CI firm purchase order, where such order for Proprietary
Material(s) conforms to the terms and conditions of this Agreement with respect
to:

                                    (a)      the price to be paid for such
                                             Proprietary Material;

                                    (b)      the amount of Proprietary Material
                                             to be delivered;

                                    (c)      the time frame for delivery of the
                                             Proprietary Material;

                                    (d)      the time frame for delivery of
                                             payment for Proprietary Material;

                                    (e)      the specifications for the
                                             Proprietary Material; and

                                    (f)      the location of the delivery of
                                             Proprietary Material;

                                                                               9
<PAGE>   10

and MPI fails to correct such failure within sixty (60) days of a written notice
of deficiency from CI, provided CI is not in default under any other provision
of this Agreement; or

                           (ii) MPI is declared insolvent pursuant to Section
365(n)(1) of the Bankruptcy Code or any similar provision of any controlling
state insolvency law(s);

until such time as MPI resumes manufacturing of such Proprietary Materials in
quantities sufficient to supply CI with Proprietary Materials consistent with
the terms and conditions set forth in this Agreement, and MPI notifies CI that
MPI is prepared to resume exclusive manufacture of such Proprietary Materials.

                  5.1.10 In the event that the provisions of Section 5.1.9
apply, MPI shall transfer to CI that documentation possessed by MPI that would
be reasonably necessary for a person with a Bachelor of Science degree in
organic chemistry and reasonably skilled in the relevant manufacturing and/or
analytical processes, to reproduce and manufacture the Proprietary Material(s)
previously available from MPI under the terms of this Agreement, including
without limitation, lists of raw materials, and their commercial sources,
synthesis and purification protocols, and methods and procedures for the
characterization and quality control. To the extent such documentation contains
Confidential Information of MPI, CI shall institute reasonable measures to
prevent its unauthorized use and/or disclosure.

         5.2 Supply. Subject to the terms and conditions of Section 5.1 and this
Section 5.2, MPI shall manufacture Licensed Materials in accordance with CI
Specifications, and shall supply CI with CI's requirements for Licensed
Materials. At CI's request, MPI shall also supply CI with Non-Proprietary
Material(s) subject to Sections 5.2.4, 5.2.5 and 5.5 (i) non-exclusively as
Stock Item(s) or (ii) exclusively as a Custom Product(s) or non-exclusively,
pursuant to Section 5.2.5, at CI's option. CI shall have the right to repackage
Licensed Materials (subject to the terms and conditions of Sections 2.1-2.3, 6.2
and 6.5), and Non-Proprietary Materials supplied by MPI hereunder

                  5.2.1 Forecasts. For so long as MPI is supplying Licensed
Materials to CI hereunder, at least thirty (30) days prior to the start of any
calendar quarter ("Q1"), CI shall provide MPI with a rolling written forecast of
the quantities of Licensed Materials (on a product-by-product basis) estimated
to be required on a quarter-by-quarter basis for four (4) consecutive quarters
("Q1" to "Q4", respectively). Each forecast shall indicate the estimated
quantities of Licensed Materials. CI will provide such forecasts as a means of
production planning only and such forecasts shall not constitute a binding
obligation upon MPI or CI. CI may also provide forecasts of its estimated
requirements for Non-Proprietary Materials, at its option, if CI desires such
estimates to be included in MPI's production planning for the purposes of
extending the provisions of Sections 5.2.3 to such Non-Proprietary Materials.

                  5.2.2 Form of Order. CI's orders shall be made pursuant to a
written purchase order which is in a form mutually acceptable to the parties.
MPI shall use reasonable efforts to notify CI within ten (10) days from receipt
of an order of its ability to fill quantities ordered thereunder, subject to
Section 5.2.3 below.

                                                                              10
<PAGE>   11

                  5.2.3 Shipping. All Licensed Materials and Non-Proprietary
Materials delivered pursuant to the terms of this Section 5.2 shall be suitably
packed for shipment by MPI, marked for shipment to the destination point
indicated in CI's purchase order. Unless otherwise agreed between the parties in
writing, orders for less than twenty-five (25) units of the same Stock Item for
which MPI has previously received a forecast pursuant to Section 5.2.1 shall be
shipped to CI within five (5) business days of receipt of the order; orders for
twenty-five (25) units or more of the same Stock Item shall be shipped within
thirty (30) days of receipt of the order. The shipment schedules for orders of
Custom Products will be determined at the time such order is placed, in
accordance with MPI's standard completion schedules for custom synthesis. All
Licensed Materials and Non-Proprietary Materials shipped to CI will be
delivered FOB (U.C.C.) the shipping point. All shipping and insurance costs, as
well as any special packaging expenses, shall be paid by CI.

                  5.2.4 Prices. MPI shall provide to CI all Licensed Materials
and Non-Proprietary Materials to CI for use in Finished Products and Services as
follows:

                           (i) MPI shall provide Stock Items at MPI's standard
retail rates as set forth in MPI's website for the period in which the purchase
order was submitted. CI shall be entitled to any standard quantity discounts MPI
offers to industry customers  [*]  .

                           (ii) In addition to the discount set forth above, CI
shall receive an additional discount rebate within thirty (30) days after the
conclusion of a semi-annual period, for aggregate purchases of Licensed
Materials and Non-Proprietary Materials that are Stock Items from the attached
MPI Technology Packages according to the following schedule:

                                    (1) for aggregate annual purchases of less
than  [*]  no discount rebate, regardless of the amount purchased;

                                    (2) for aggregate annual purchases of at
least  [*] ; a discount rebate that is  [*]  of such annual aggregate purchases
within the specified range;

                                    (3) for aggregate annual purchases of at
least  [*]  a discount rebate that is  [*]  of such annual aggregate purchases
within the specified range;

                                    (4) for aggregate annual purchases of at
least  [*]  ; a discount rebate that is  [*]  of such annual aggregate purchases
within the specified range.

                           (iii) MPI shall provide Custom Products at prices to
be negotiated in good faith, subject to Sections 5.1.3, 5.1.5, 5.1.7 and 5.2.5.
Prior to determination of the price to be paid for such Custom Product, MPI and
CI shall agree on the degree of exclusivity (pursuant to Section 5.2.5) as well
as the quality control specifications and packaging specifications for such
Custom Product, which agreed specifications shall become the CI Specifications
for such Custom Product, and in the event such Custom Product shall become a
Stock Item, subject to Sections 5.1.3 and 5.2.5, for such Stock Item. Such
Custom Products shall not be included in the annual aggregate purchases

     "CONFIDENTIAL [*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT
OF 1933, AS AMENDED."

                                                                              11
<PAGE>   12

that qualify for the discount rebate, unless and until such Custom Products
shall become available as Stock Items.

                  5.2.5 Prior to MPI accepting an order for a Custom Product, CI
and MPI shall agree in writing whether MPI may convert such Custom Product into
a Stock Item or produce it as a custom product for other party/ies, without
further approval from CI, to address CI's concerns about preserving CI's trade
secrets and MPI's concerns about maintaining flexibility in offering MPI's
technology to third parties for uses other than those exclusively licensed to
CI.

                  5.2.6 Invoicing and Payment. MPI shall submit an invoice to CI
upon shipment of Licensed Materials and Non-Proprietary Materials ordered by CI.
All invoices shall be sent to CI's address for notices hereunder and marked
"Attention: Accounting Department." Each such invoice shall state CI's aggregate
price therefor in a given shipment, plus any insurance, taxes or other costs
incident to the purchase or shipment initially paid by MPI but to be borne by CI
hereunder. Payment shall be made within thirty (30) days after the invoice is
sent to CI.

         5.3 Product Acceptance/Returns.

                  5.3.1 Unless agreed otherwise in writing prior to or
concurrently with acceptance of an order in accordance with Section 5.2.2, any
Licensed Materials and Non-Proprietary Materials supplied hereunder shall
conform at the time of shipment to MPI's internal specifications for research
grade reagents and packaged according MPI's internal packaging protocols.

                  5.3.2 Unless agreed otherwise in writing prior to or
concurrently with acceptance of an order in accordance with Section 5.2.2, any
Custom Products supplied hereunder shall conform at the time of shipment to CI
Specifications.

                  5.3.3 The parameters for evaluating the performance of
Licensed Materials in a particular application undertaken by CI are beyond the
control of MPI and, while such parameters may determine the suitability of
materials for such application, such parameters shall not be used to determine
acceptance of materials. Only written specifications agreed to between the
parties shall be used to determine acceptance of materials supplied by MPI.

                  5.3.4 Each shipment of Licensed Materials and Non-Proprietary
Materials hereunder shall be accompanied by a certificate of analysis for each
lot therein as well as such customs and other documentation as is necessary or
appropriate for shipment of materials from MPI to CI.

                  5.3.5 MPI will provide, upon CI's request, those test
procedures and test data that are the basis for the certificate of analysis
pertaining to Licensed Materials and Non-Proprietary Materials.

                  5.3.6 Without limiting the foregoing, if any Licensed
Materials or Non-Proprietary Materials supplied hereunder fail to conform to the
applicable CI Specifications or certificate of analysis, then CI shall promptly
notify MPI and present reasonable evidence to MPI of such nonconformity, if
requested to do so. Subject to the limitations in Sections 5.1, 5.2.4, 5.3.1,
5.3.2 and 5.3.3, MPI agrees to replace, at no additional expense to CI, such
nonconforming Licensed

                                                                              12
<PAGE>   13

Materials or Non-Proprietary Materials with conforming product within thirty
(30) days after receipt of CI's notification under this Section 5.3.

                  5.3.7 In the event that MPI disputes CI's evidence of
nonconformity, MPI may, at its own expense, request that an independent third
party tester selected by the parties analyze any unit of Licensed Materials or
Non-Proprietary Materials rejected by or on behalf of CI for nonconformity and,
if the independent third party tester determines that any such unit of Licensed
Materials or Non-Proprietary Materials was conforming, then CI shall be
responsible for payment of such units and for such analysis.

                  5.3.8 All returns of Licensed Materials and Non-Proprietary
Materials shall be in accordance with a mutually agreeable product return
protocol.

         5.4 Allocation. In the event that MPI is unable (due to force majeure
or otherwise) to supply both MPI's worldwide requirements of Licensed Materials
or Non-Proprietary Materials, and quantities of such Materials forecast pursuant
to Section 5.2.1 and ordered by CI under Section 5.2.2 above, MPI shall allocate
the quantities of such Licensed Materials or Non-Proprietary that MPI has in
inventory, and that MPI is able to produce, so that CI receives at least its
proportional share of available supplies as determined based on reasonable
forecasts of the requirements of CI, MPI and other third parties (taking into
consideration past requirements for such Materials relative to past forecasts).

         5.5 Compliance with Regulatory Agency Requirements. MPI shall comply
with all laws and regulations applicable to the manufacture of Licensed
Materials and Non-Proprietary Materials. Upon CI's prior written approval, such
approval not to be unreasonably withheld, CI shall reimburse MPI up to $400 for
each low volume exemption ("LVE") filing required for non-research use, in
performance of MPI's obligations hereunder. Non-Proprietary Materials for which
such non-research use is intended shall be identified by CI prior to such
non-research use, for determination of such LVE filing requirement and for
inclusion in Exhibit C attached hereto.

                                    ARTICLE 6
              OWNERSHIP OF INTELLECTUAL PROPERTY AND PATENT RIGHTS

         6.1 Patent Prosecution. MPI shall control, at its sole expense, the
prosecution and maintenance activities pertaining to MPI Patents, using counsel
of its choice and in such countries as it deems appropriate.

         6.2 Patent Marking. CI shall use reasonable efforts to mark
advertisements, labels, and product literature that pertain to Finished Products
to mention the patent number of MPI Patents or a statement of pending patent
status, and a statement to the effect that Licensed Materials are limited to use
in the Field only.

         6.3 Patent Enforcement. If either party reasonably believes that any
MPI Technology Package is infringed or misappropriated by a third party or is
subject to a declaratory judgement action arising from such infringement, such
party shall promptly notify the other party. Both parties shall use their best
efforts in cooperating with each other to terminate such infringement or

                                                                              13
<PAGE>   14

misappropriation without litigation. If such efforts without litigation are
unsuccessful, prosecution of a third party for the infringing use of MPI's
Technology Package may be undertaken.

                  6.3.1 MPI Initiating Enforcement Actions. MPI shall have the
initial right (but not the obligation) to enjoin such misappropriation, to
enforce the MPI Patents with respect to such infringement, or to defend any
declaratory judgment with respect to the MPI Technology Package (for purposes of
this Section 6.3, any such action is herein after referred to as an "Enforcement
Action"). MPI shall keep CI reasonably informed of the progress of any such
Enforcement Action, and CI shall have the right to participate with counsel of
its own choice at its own expense.

                  6.3.2 CI Initiating Enforcement Actions. In the event that MPI
fails to initiate an Enforcement Action to protect MPI Technical Information or
to enforce the MPI Patents against a commercially significant infringement by a
third party, which infringement or misappropriation consists of the manufacture,
Sale or use of a product in the Field, within one hundred twenty (120) days of a
request by CI to initiate such Enforcement Action, CI may initiate an
Enforcement Action against such infringement with MPI's prior written approval,
which approval shall not be unreasonably withheld or delayed, and at CI's
expense. MPI's approval for initiation of an Enforcement Action notwithstanding,
CI shall not enter into any settlement of an Enforcement Action initiated by CI,
if such settlement admits the unpatentability, invalidity or unenforceability of
any MPI Patent without the written consent of MPI.

                  6.3.3 Recoveries. If a party undertakes an Enforcement Action
at its own expense, it shall be entitled to 100% of the recoveries therefrom. If
the other party chooses to join such Enforcement Action at its own expense, the
parties shall agree in advance what the apportionment of expenses and recoveries
shall be.

         6.4 Defensive Actions. If a claim, suit or proceeding (any for purposes
of this Section 6.4, an "Action") is brought against CI or MPI (the "Subject
Party") and such Action is directed to the subject of a patent or patent
application within the MPI Patents, the Subject Party shall promptly notify the
other party. As between the parties to this Agreement, the Subject Party shall
be entitled to control the defense in any such action(s); provided that the
other party shall have the right to participate in the defense or settlement
thereof at its own expense with counsel of its own choosing. Except as agreed in
writing by the other party, the Subject Party shall not enter into any
settlement of an Action, if such settlement admits the unpatentability,
invalidity or unenforceability of any MPI Patent. The Subject Party agrees to
keep the other party hereto reasonably informed of all material developments in
connection with any Action.

         6.5 MPI Trademarks. CI shall use trademarks of MPI to identify Licensed
Materials that are supplied by MPI. CI shall not use MPI's trademarks to
identify Licensed Materials if such Licensed Materials contain no components
that are supplied by MPI and CI shall not use any other of MPI's trademarks,
trade names, slogans, logos, or packaging designs (or any similar trademarks,
trade names, slogans, logos, or packaging designs), except where such use is
specifically authorized in writing by MPI in advance.

                                                                              14
<PAGE>   15

                  6.5.1 CI shall properly use all such trademarks and shall
acknowledge MPI's ownership of such trademark(s) in advertisements,
publications, and product literature. Where space is available, product labels
shall acknowledge MPI's ownership of such trademarks.

                  6.5.2 CI shall not register nor assist a third party to
register any of MPI's trademarks, trade names, slogans, logos, or packaging
designs (or any similar trademarks, trade names, slogans, logos, or packaging
designs) except as specifically authorized in writing by MPI in advance.

         6.6 Reservation. Other provisions of this Article 6 notwithstanding, in
the event that any third party shall file an infringement suit against either
party, where the suit alleges that a Finished Product or Service, only when used
as offered for Sale by CI, infringes the patent of such third party, (i.e. it is
the particular method of use offered by CI that is the issue, rather than the
materials furnished by MPI); then CI shall have the option to discontinue such
use or to indemnify and hold MPI harmless from and against all proceedings and
claims by third parties arising out of the use or sale of Finished Products or
Services in the allegedly infringing manner. Where the suit alleges that it is a
Licensed Material that infringes the patent of such third party, MPI shall have
the option to waive its exclusive right to the manufacture of such Licensed
Material in accordance with Section 5.1.8 above, but not to otherwise limit the
access of CI to such Licensed Material.

                                    ARTICLE 7
                         REPRESENTATIONS AND WARRANTIES

         7.1 MPI Warranties. MPI hereby represents, warrants and covenants to CI
that (i) it has the full right and authority to enter into this Agreement and
grant the rights and licenses granted herein; (ii) it has not previously granted
and will not grant any rights in conflict with the rights and licenses granted
herein; (iii) to MPI's knowledge and belief, MPI is not aware of any third party
intellectual property rights that are infringed by Licensed Materials, and there
are no existing or threatened actions, suits or claims pending against it with
respect to its right to enter into and perform its obligations under this
Agreement; and (iv) to MPI's knowledge and belief, the Licensed Materials are
useful for the methods described or claimed in MPI Patents, but MPI MAKES NO
WARRANTIES OR REPRESENTATIONS OF MERCHANTABILITY OR SUITABILITY FOR A PARTICULAR
PURPOSE.

         7.2 CI Warranties. CI hereby represents, warrants and covenants that it
has the full right and authority to enter into this Agreement.

                                    ARTICLE 8
                                 CONFIDENTIALITY

         8.1 Confidential Information. Except as expressly provided herein, the
parties agree that, for the term of this Agreement and for five (5) years
thereafter, the receiving party shall not publish or otherwise disclose and
shall not use for any purpose any information furnished to it by the other party
hereto pursuant to this Agreement which if disclosed in tangible form is marked
"confidential" or with other similar designation to indicate its confidential or
proprietary nature, or if disclosed

                                                                              15
<PAGE>   16

orally is confirmed as confidential (any oral disclosures must be identified in
writing as confidential within (30) thirty days of such disclosure) or
proprietary by the party disclosing such information at the time of such
disclosure (collectively, "Confidential Information"). Notwithstanding the
foregoing, it is understood and agreed that Confidential Information shall not
include information that, in each case as demonstrated by written documentation:

                  8.1.1 was already known to the receiving party, other than
under an obligation of confidentiality, at the time of disclosure;

                  8.1.2 was generally available to the public or otherwise part
of the public domain at the time of its disclosure to the receiving party;

                  8.1.3 became generally available to the public or otherwise
part of the public domain after its disclosure and other than through any act or
omission of the receiving party in breach of this Agreement; or

                  8.1.4 was subsequently lawfully disclosed to the receiving
party by a person other than a party hereto or developed by the receiving party
without reference to any information or materials disclosed by the disclosing
party.

                  8.1.5 Sections 8.1.1 through 8.1.4 notwithstanding,
information disclosed by one party to another shall still be deemed Confidential
Information of the disclosing party subject to the protection of this Section
8.1 if such disclosed information is

                           (i) a specific embodiment that is only generally
described by information in the public domain or the receiving party's
possession or

                           (ii) a combination that can be pieced together and
reconstructed from multiple sources, none of which shows the whole combination
of materials, its principle of operation, and method of use.

         8.2 Permitted Disclosures. Notwithstanding the provisions of Section
8.1 above, each party hereto may use and disclose the other's Confidential
Information to the extent such use and disclosure is reasonably necessary, in
defending litigation, complying with applicable governmental regulations,
submitting information to tax or other governmental authorities or in exercising
its rights hereunder, provided that if a party is legally required to make any
such disclosure of the other party's Confidential Information, to the extent it
may legally do so, it will give reasonable advance written notice to the latter
party of such disclosure and, save to the extent inappropriate in the case of
patent applications, will use its reasonable efforts to secure confidential
treatment of such Confidential Information prior to its disclosure (whether
through protective orders or otherwise).

                                    ARTICLE 9
                                 INDEMNIFICATION

         9.1 Indemnification of CI. MPI shall indemnify each of CI and its
directors, officers and employees and the successors and assigns (only as
authorized under Section 11.7) of the foregoing

                                                                              16
<PAGE>   17

(collectively, the "CI Indemnitees"), and hold each CI Indemnitee harmless from
and against any and all liabilities, damages, settlements, claims, actions,
suits, penalties, fines, costs or expenses (including, without limitation,
reasonable attorneys' fees and other expenses of litigation) incurred by any CI
Indemnitee arising from or occurring as a result of any claim, action, suit, or
other proceeding brought by third parties against a CI Indemnitee arising from
or occurring as a result of the gross negligence or willful tortious misconduct
of a MPI Indemnitee.

         9.2 Indemnification of MPI. CI shall indemnify each of MPI and its
directors, officers and employees and the successors and assigns of the
foregoing (collectively, the "MPI Indemnitees"), and hold each MPI Indemnitee
harmless from and against any and all liabilities, damages, settlements, claims,
actions, suits, penalties, fines, costs or expenses (including, without
limitation, reasonable attorneys' fees and other expenses of litigation)
incurred by any MPI Indemnitee arising from or occurring as a result any claim,
action, suit, or other proceeding brought by third parties against a MPI
Indemnitee arising from or occurring as a result of the gross negligence or
willful tortious misconduct of a CI Indemnitee.

         9.3 Procedure. A party (for purposes of this Section 9.3, the
"Indemnitee") that intends to claim indemnification under any provision of this
Agreement shall: (i) promptly notify the indemnifying party (the "Indemnitor")
in writing of any claim, action, suit, or other proceeding brought by third
parties in respect of which the Indemnitee, or their directors, officers,
employees, successors or assigns intend to claim such indemnification hereunder;
(ii) provide the Indemnitor sole control of the defense and/or settlement
thereof, and (iii) provide the Indemnitor, at the Indemnitor's request and
expense, with reasonable assistance and full information with respect thereto.
Notwithstanding the foregoing, the indemnity obligation in this Article 9 shall
not apply to amounts paid in settlement of any loss, claim, damage, liability or
action if such settlement is effected without the consent of the Indemnitor, to
the extent such consent is not withheld unreasonably or delayed. Without
limiting the foregoing provisions of this Section 9.3, the Indemnitor shall keep
the Indemnitee reasonably informed of the progress of any claim, suit or
proceeding under this Section 9.3 and the Indemnitee shall have the right to
participate in any such claim, suit or proceeding with counsel of its choosing
at its own expense.

                                   ARTICLE 10
                              TERM AND TERMINATION

         10.1 Agreement Term. This Agreement shall become effective as of the
Effective Date and shall continue in full force and effect until the expiration,
revocation or invalidation of the last issued patent within the MPI Patents
("Term").

                                                                              17
<PAGE>   18

         10.2 Effect of Expiration.

                  10.2.1 Accrued Obligations. Expiration of this Agreement for
any reason shall not release either party hereto from any liability which, at
the time of such expiration, has already accrued to the other party or which is
attributable to a period prior to such expiration nor preclude either party from
pursuing all rights and remedies it may have hereunder or at law or in equity
with respect to any breach of this Agreement.

         10.3 Termination.

                  10.3.1 In the event of a material breach of a party of its
obligations hereunder, the nonbreaching party shall be entitled to terminate
this Agreement upon written notice to the breaching party, if such breach is not
cured within thirty (30) days after written notice is given by the nonbreaching
party to the breaching party specifying the breach.

                  10.3.2 In the event that CI terminates its rights to all MPI
Technology Packages pursuant to Section 2.6, CI may terminate this Agreement
upon sixty (60) days written notice to MPI.

         10.4 Effect of Termination.

                  10.4.1 Accrued Obligations. Termination of this Agreement for
any reason shall not release either party hereto from any liability which, at
the time of such termination, has already accrued to the other party or which is
attributable to a period prior to such termination nor preclude either party
from pursuing all rights and remedies it may have available hereunder or at law
or equity with respect to any breach hereunder.

                  10.4.2 Return of Materials. Upon any termination of this
Agreement, CI and MPI shall promptly return to the other party all Confidential
Information received from the other party (except one copy which may be retained
for archival purposes only).

         10.5 Survival. Sections 5.3, 10.2, 10.4, 11.1 and 11.6, and Articles
6,7,8 and 9 shall survive the expiration or termination of this Agreement for
any reason.

                                   ARTICLE 11
                                  MISCELLANEOUS

         11.1 Governing Law. This Agreement and any dispute arising from the
performance or breach hereof shall be governed by and construed and enforced in
accordance with, the laws of the State of New York, without reference to
conflicts of laws principles.

         11.2 Force Majeure. Nonperformance of any party (except for payment of
amounts due hereunder, and as provided in Section 5.1.9) shall be excused to the
extent that performance is rendered impossible by strike, fire, earthquake,
flood, governmental acts or orders or restrictions, or any other reason,
including failure of suppliers, where failure to perform is beyond the
reasonable

                                                                              18
<PAGE>   19

control of the nonperforming party. Without limiting the foregoing, the party
subject to such inability shall use reasonable efforts to minimize the duration
of any force majeure event.

         11.3 No Implied Waivers; Rights Cumulative. No failure on the part of
MPI or CI to exercise and no delay in exercising any right under this Agreement,
or provided by statute or at law or in equity or otherwise, shall impair,
prejudice or constitute a waiver of any such right, nor shall any partial
exercise of any such right preclude any other or further exercise thereof or the
exercise of any other right.

         11.4 Independent Contractors. Nothing contained in this Agreement is
intended implicitly, or is to be construed, to constitute MPI or CI as partners
in the legal sense. No party hereto shall have any express or implied right or
authority to assume or create any obligations on behalf of or in the name of any
other party or to bind any other party to any contract, agreement or undertaking
with any third party.

         11.5 Notices. All notices, requests and other communications hereunder
shall be in writing and shall be personally delivered or sent by registered or
certified mail, return receipt requested, postage prepaid; facsimile
transmission (receipt verified); or express courier service (signature
required), in each case to the respective address or fax number specified below,
or such other address or fax number as may be specified in writing to the other
parties hereto:

                  CI:   Cellomics, Inc.
                        635 William Pitt Way
                        Pittsburgh, PA 15238
                        Attn: Intellectual Property Manager
                        Fax: (412) 826-3895

                  MPI:  Molecular Probes, Inc.
                        P.O. Box 22010
                        Eugene, OR 97402-0469
                        Attn: Legal Department
                        Fax: (541) 344-6504

         11.6 Limitation of Liability. NEITHER PARTY SHALL BE LIABLE TO THE
OTHER PARTY FOR ANY SPECIAL, CONSEQUENTIAL, EXEMPLARY OR INCIDENTAL DAMAGES
(INCLUDING LOST OR ANTICIPATED REVENUES OR PROFITS RELATING TO THE SAME),
ARISING FROM ANY CLAIM RELATING TO THIS AGREEMENT, WHETHER SUCH CLAIM IS BASED
ON CONTRACT, TORT (INCLUDING NEGLIGENCE) OR OTHERWISE, EVEN IF AN AUTHORIZED
REPRESENTATIVE OF SUCH PARTY IS ADVISED OF THE POSSIBILITY OR LIKELIHOOD OF
SAME.

         11.7 Assignment. This Agreement shall not be assignable by either party
to any third party except that CI may assign this Agreement to an entity that
acquires substantially all of its business or assets, whether by merger,
transfer of assets, or otherwise ("Acquisition"); provided, however, (i) the
acquirer pay to MPI a transfer fee of $100,000 within thirty (30) days after the
effective date of the Acquisition; and (ii) effective upon the second
anniversary of the effective date of the Acquisition, the total annual royalty
payments and the total annual purchase payments to MPI for Licensed Materials
increase to a level that is twice that of the corresponding annual payments
payable to MPI by CI in the year that immediately preceded the effective date of
the Acquisition. Such assignment shall be effective immediately upon the payment
set forth in Section 11.7(i) and continue in full force unless acquiror fails to
meet the conditions set forth in Section 11.7(ii). In the event the conditions
set forth in this Section 11.7 are not met, this Agreement shall immediately
terminate and the provisions of Section 10.4 shall apply.

     "CONFIDENTIAL [*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT
OF 1933, AS AMENDED."

                                                                              19
<PAGE>   20

         11.8 Modification. No amendment or modification of any provision of
this Agreement shall be effective unless in writing signed by both parties
hereto. No provision of this Agreement shall be varied, contradicted or
explained by any oral agreement, course of dealing or performance or any other
matter not set forth in an agreement in writing and signed by both parties
hereto.

         11.9 Severability. If any provision hereof should be held invalid,
illegal or unenforceable in any jurisdiction, the parties shall negotiate in
good faith a valid, legal and enforceable substitute provision that most nearly
reflects the original intent of the parties and all other provisions hereof
shall remain in full force and effect in such jurisdiction and shall be
liberally construed in order to carry out the intentions of the parties hereto
as nearly as may be possible. Such invalidity, illegality or unenforceability
shall not affect the validity, legality or enforceability of such provision in
any other jurisdiction.

         11.10 Confidential Terms. Except as expressly provided herein, each
party agrees not to disclose any terms of this Agreement to any third party
without the consent of the other party, except as required by securities or
other applicable laws, to prospective and other investors and such party's
accountants, attorneys and other professional advisors.

         11.11 Counterparts. This Agreement may be executed in one or more
counterparts, each of which shall be deemed an original, and all of which
together, shall constitute one and the same instrument.

         11.12 Headings. Headings used herein are for convenience only and shall
not in any way affect the construction of or be taken into consideration in
interpreting this Agreement.

         11.13 Entire Agreement. This Agreement (including the Exhibits hereto,
incorporated herein by reference) constitute the entire agreement, both written
or oral, with respect to the subject matter hereof, and supersede all prior or
contemporaneous understandings or agreements, whether written or oral, between
MPI and CI with respect to such subject matter.

[signature block next page]

###

###

                                                                              20
<PAGE>   21

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly
executed and delivered in duplicate originals as of the date first above
written.

MOLECULAR PROBES, INC.

By: /s/ Rosaria P. Haugland
    ---------------------------
Name:  Rosaria P. Haugland
       ------------------------
Title: Vice President
       ------------------------

CELLOMICS, INC.

By: /s/ D. Lansing Taylor
    ---------------------------
Name:  D. Lansing Taylor
       ------------------------
Title: President & CEO
       ------------------------
<PAGE>   22

                               EXHIBIT A [*]

(Page 1)

                               -------------
                                    [*]
                                  Patents
                                 (Number)
                               -------------
                                    US
                                 4,774,339
                               -------------
                                    US
                                 5,274,113
                               -------------
                                    US
[ * ]                            5,451,663                                [ * ]
                               -------------
                                    US
                                 5,274,113
                               -------------
                                    US
                                 5,451,663
                               -------------
                                    US
                                 5,433,896
                               -------------
                                    US
                                 5,314,805
                               -------------

                               -------------

     "CONFIDENTIAL [*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT
OF 1933, AS AMENDED."

<PAGE>   23

(Page 2)

                               -------------
                                    [*]
                                  Patents
                                 (Number)
                               -------------
                                    US
                                 5,362,628
                               -------------
                                    US
                                 5,576,424
                               -------------
                                    US
                                 5,459,268
                               -------------
                                    US
[ * ]                            5,686,261                              [ * ]
                               -------------
                                    [*]

                               -------------
                                    [*]

                               -------------
                                    [*]
                                  Patents
                                 (Number)
                               -------------
                                    US
                                 5,869,689
                               -------------
                                    US
                                 4,774,339
                               -------------
                                    US
                                 5,274,113
                               -------------

     "CONFIDENTIAL [*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT
OF 1933, AS AMENDED."

<PAGE>   24

(Page 3)
                                -------------
                                     [*]
                                   Patents
                                  (Number)
                                -------------
                                     US
                                  5,321,130
                                -------------
                                     US
                                  5,410,030
                                -------------
                                     US
[ * ]                             5,582,977                           [ * ]
                                -------------
                                     US
                                  5,798,276
                                -------------
                                     [*]

                                -------------
                                     [*]

                                -------------

     "CONFIDENTIAL [*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT
OF 1933, AS AMENDED."

<PAGE>   25

(Page 4)

                    [ * ]

     "CONFIDENTIAL [*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT
OF 1933, AS AMENDED."<PAGE>   1
                                                                   Exhibit 10.10

                 DEVELOPMENT, MANUFACTURING AND SUPPLY AGREEMENT

         This is an Agreement, effective this 3rd day of February, 2000, between
Carl Zeiss Jena GmbH, 07740 Jena, Germany (hereinafter ZEISS) and Cellomics,
Inc., 635 William Pitt Way, Pittsburgh, PA 15238 (hereinafter CELLOMICS);

         WHEREAS, ZEISS has expertise and intellectual property in optical
detection systems, systems integration, control software, HTS/UHTS systems and
manufacturing;

         WHEREAS, CELLOMICS has expertise and intellectual property in
technologies related to High Content Screening ("HSC");

         WHEREAS, CELLOMICS desires to have ZEISS cooperatively develop,
manufacture and supply an ArrayScan Kinetics Reader and an ArrayScan Kinetics
Workstation to CELLOMICS' specifications;

         WHEREAS, the parties have heretofore entered into a joint
"Co-Marketing, Manufacturing, Sales and Support Agreement" (the "Former
Agreement"), effective April 14, 1998;

         WHEREAS, the parties are independently negotiating an agreement (the
"Sales Agreement") providing for the distribution of ZEISS' UHTS Systems in
North America by CELLOMICS;

                                       -1-

<PAGE>   2

         WHEREAS, the parties are determined to update and supersede the Former
Agreement.

         NOW, THEREFORE, in consideration of the covenants and conditions
contained herein, the parties, intending to be legally bound, agree as follows:

                                    ARTICLE I

                                   DEFINITIONS

         1. Specific Definitions. For purposes of this Agreement, the following
definitions shall apply:

         1.1 "Microplate" shall mean the plastic and/or glass plate having 96
         wells or multiples (e.g. 384, 1536, 3456 or more wells) or divisions
         (e.g. 12, 24, 48 or more wells) and dimensions ca. 12.5 and 8.5 cm.

         1.2 "HTS" shall mean optics, fluidics, robotics, storage, computers,
         software and other peripheral devices used to conduct intensity
         measurements of molecular interactions in microplates, excludes spatial
         measurements within cells.

         1.3 "FCS" shall mean single molecule detection of stimulated
         fluorescence in optical volume elements smaller than one nanolitre for
         correlation analysis of molecule movements.

                                       -2-

<PAGE>   3

         1.4 High Content Screening ("HCS") shall mean image  [*]  This excludes
         any other applications, and specifically excludes HTS and FCS.

         1.5 ArrayScan Kinetics Reader ("ASK Reader") shall mean the combination
         of optical, mechanical, environmental control components and device
         control software constituting an instrument as defined in Exhibits 1.0
         and 4.0 which performs the following combination of functions:

                                      [*]

         The ASK Reader is the same unit as that intended for use in the ASK
         Workstation (defined below).

         1.6 ArrayScan Kinetics Workstation ("ASK Workstation") shall mean an
         instrument which integrates the ASK Reader and other peripheral devices
         as specified herein on Exhibits 1.0 and 4.0.

     "CONFIDENTIAL [*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT
OF 1933, AS AMENDED."

                                       -3-

<PAGE>   4

         1.7 "Sales Agreement" shall mean the Sales and Marketing Agreement with
         regard to ZEISS' UHTS Systems being independently negotiated between
         the parties at this time, as the same may be amended from time to time.

         1.8 "Former Agreement" shall mean the "Co-Marketing, Manufacturing,
         Sales and Support Agreement and development of OEM Array Scan for
         Cellomics by Zeiss" between the parties, effective April 14, 1998.

         1.9 "Intellectual Property" shall be defined as any invention,
         discovery, improvements, device, design, apparatus, practice, process,
         method, product, program, database, or compound, whether patentable or
         copyrightable or not. Intellectual Property rights on the ASK
         Workstation and ASK Reader are defined and categorized on Exhibit 4.0.

         1.10 "OEM Development" shall be defined as any Intellectual Property
         made by either party or a third party employed thereby specified as
         such in Exhibit 4.0 and which relates to HCS and which was developed
         and manufactured specifically for the ASK Project (defined in Article
         2.1 below).

         1.11 "ZEISS Technology" shall be defined as Intellectual Property which
         is the property of ZEISS.

                                       -4-

<PAGE>   5

         1.12 "CELLOMICS Technology" shall be defined as Intellectual Property
         which is property of CELLOMICS.

         1.13 "Third Party OEM Developments" shall be defined as all OEM
         Developments made specifically for the ASK Project by third parties
         employed by either ZEISS or CELLOMICS.

         1.14 "Third Party Technology" shall be defined as Intellectual Property
         which is the property of a third party.

                                   ARTICLE II

                        OEM DEVELOPMENT AND MANUFACTURING

         2.1 ZEISS is in the process of cooperatively designing and
manufacturing to CELLOMICS specifications as set forth on Exhibits 1.0 and 2.0
(which are attached hereto and made a part hereof) two OEM products to be known
as the ArrayScan Kinetics Reader ("ASK Reader") and the ArrayScan Kinetics
Workstation ("ASK Workstation") in accordance with the development schedule set
forth on Exhibit 3.0 parts A and B (which is attached hereto and made a part
hereof) (the "ASK Project").

         2.2 CELLOMICS will, on an ongoing basis, as necessary, advise and
consult with ZEISS on design and performance parameters for the ASK Project.

                                       -5-

<PAGE>   6

         2.3 ASK Readers and ASK Workstations manufactured by ZEISS will be sold
under the CELLOMICS label, but the ZEISS label will he affixed to the ASK
Readers and ASK Workstations in such manner as will in a commercially reasonable
manner acknowledge the use therein of ZEISS Technology as categorized on Exhibit
4.0.

         2.4 The parties hereby establish a Management Committee for the ASK
Project including coordination and development of the ASK Reader and ASK
Workstation and to recommend other products and services to be explored and
developed by the parties, jointly or severally.

                                   ARTICLE III

                              SOFTWARE DEVELOPMENT

         3.1 CELLOMICS has developed data analysis and data management software
for the ASK Project, while ZEISS has developed instrument device control
software as part of the ASK Project. Software development responsibilities for
ZEISS are as set forth in Exhibit 2.0 (which is attached hereto and is made a
part hereof); those responsibilities include all software components not
specifically assigned to CELLOMICS.

         3.2 Software interface specifications have been jointly defined to make
software compatible between ZEISS systems and the ASK Reader and the ASK
Workstation and are included in Exhibit 2.0.

                                       -6-

<PAGE>   7

                                   ARTICLE IV

                ARRAYSCAN KINETICS READER AND ARRAYSCAN KINETICS
                    WORKSTATION DEVELOPMENT AND MANUFACTURING

         4.1 ZEISS has designed and is manufacturing, in accordance with
CELLOMICS' specifications, the ASK Reader and ASK Workstation as part of the ASK
Project. The parties agree that the device control software and hardware
currently embodied in the ASK Reader is partly based on ZEISS Technology and is
partly an OEM Development to the specifications of CELLOMICS specifically for
the ASK Project. The ASK Workstation includes the ASK Reader and various
components manufactured by third parties as well as components developed by
ZEISS to CELLOMICS' specification needed to integrate and coordinate an
efficient, effective flow through the ASK Workstation. All parts of the ASK
Reader, the ASK Workstation and the other components mentioned above are
categorized on Exhibit 4.0 (which is attached hereto and made a part hereof).
Milestones for the development and production of the ASK Reader and ASK
Workstation are set forth in Exhibit 3.0 (which is attached hereto and made a
part hereof).

         4.2 ZEISS and CELLOMICS agree that the OEM development cost ("Agreed
Sum") to meet CELLOMICS' specifications incurred by ZEISS to date and to be
incurred through completion of development is DM 4,000,000, which includes the
costs to  [*]. ZEISS agrees to provide documentation of the Agreed Sum within
thirty (30) days of the date first above written. ZEISS agrees to ship to
CELLOMICS one of the prototype ASK Workstations on or before February 18, 2000,
if for any reason this Agreement has not been executed by February 28, 2000,
said

     "CONFIDENTIAL [*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT
OF 1933, AS AMENDED."

                                       -7-

<PAGE>   8

prototype ASK Workstation shall be returned to ZEISS at CELLOMICS' expense.
ZEISS shall temporarily retain the second prototype ASK Workstation to
facilitate the full acceptance testing being performed by CELLOMICS. The second
prototype ASK Workstation shall be delivered to CELLOMICS within thirty (30)
days following the completion of the first production unit and CELLOMICS'
request for delivery. CELLOMICS agrees to pay the Agreed Sum in two (2) equal
installments as follows:

         A.  DM 2,000,000  shall be paid to ZEISS within thirty (30) days
         after the execution of this Agreement, completion of the FACT
         (= Factory Acceptance Test) of the first prototype (already performed
         and passed) and installation and proof of identical functioning at
         CELLOMICS' site compared to the FACT of the first prototype.

         B.  DM 2,000,000  shall be paid to ZEISS within six (6) months after
         acceptance of the first production unit of the ASK Workstation which is
         that furnished unit ready for sale and shipment to CELLOMICS' Customers
         following acceptance (defined in Paragraph 4.4 below).

         4.3 At all times prior to, upon and after the execution of this
Agreement, CELLOMICS was, is and shall be and be deemed to be the owner of all
OEM Developments embodied in all components categorized in Exhibit 4.0 (which is
attached hereto and made a part hereof) as OEM Developments, Third Party OEM
Developments or CELLOMICS Technology including both Intellectual Property
generated and extant on

                                       -8-

<PAGE>   9

the date first above written and any Intellectual Property involved in such
components which is applied thereafter at any time and from time to time,
excluding the components categorized as ZEISS Technology or Third Party
Technology. Further, ZEISS shall deliver to CELLOMICS within sixty (60) days of
the acceptance of the first prototype in Pittsburgh, all existing development
designs, drawings, prints, materials, documents and specifications pertaining
to the ASK Reader and ASK Workstation both as whole integrated instruments and
the components of the ASK Reader and ASK Workstation excluding only the detailed
design of that part of such components which embody ZEISS Technology and Third
Party Technology as categorized in Exhibit 4.0 (which is attached hereto and
made a part hereof). ZEISS will provide drawings showing overall dimensions and
mounting requirements for all ZEISS Technology and/or Third Party Technology.
Notwithstanding the foregoing, ZEISS will provide the production designs,
drawings, prints, materials, documents and specifications pertaining to the ASK
Reader and ASK Workstation within ninety (90) days prior to the end of the
Exclusive Supply Period (defined in Article 5.1 below).

         4.4 The working prototypes and/or series production units of the ASK
Reader and ASK Workstation shall be deemed to be accepted by CELLOMICS at such
time as CELLOMICS certifies in writing the successful execution on the prototype
and/or a series production unit in Jena of the applicable acceptance test
protocol set forth in Exhibit 5.0 ("Acceptance") (which is attached hereto and
made a part hereof).

         4.5 Any design changes or modifications in the ASK Reader and/or ASK

                                       -9-

<PAGE>   10

Workstation desired by CELLOMICS shall be implemented if mutually agreed by
ZEISS and CELLOMICS. In the event that such design changes or modifications
result in costs that cause the Agreed Sum to be exceeded or delays that extend
the development and/or production schedule, ZEISS will provide to CELLOMICS a
written proposal that includes the reasonable cost and changes to the time
schedule. Such design changes will be implemented by ZEISS upon written
acceptance of the proposal. Following Acceptance of the ASK Reader and ASK
Workstation by CELLOMICS, the costs of any system upgrades (hardware or
software), if technically feasible, will be paid by CELLOMICS in accordance with
specific development-cost proposals to be prepared by ZEISS and approved in
writing by CELLOMICS.

                                    ARTICLE V

                                EXCLUSIVE SUPPLY

5.1 From the date first above written, extending to that time which ends on
September 30, 2002  ("Exclusive Supply Period"), CELLOMICS agrees that it shall
purchase any and all ASK Readers and ASK Workstations exclusively from ZEISS,
and during the Exclusive Supply Period, ZEISS agrees that it will not utilize,
license, sell, offer to sell, or develop devices or systems for HCS which embody
the OEM Developments or ASK Workstation and ASK Reader according to Exhibit 4.0
and which are competitive with those developed pursuant to the ASK Project,
("NEW PRODUCTS") and will cooperate in developing NEW PRODUCTS for HCS
exclusively in conjunction with CELLOMICS. In the event CELLOMICS does not
affirmatively agree to the mutual and prompt development and

     "CONFIDENTIAL [*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT
OF 1933, AS AMENDED."

                                      -10-

<PAGE>   11

manufacture by CELLOMICS and ZEISS of such NEW PRODUCTS, within two months from
ZEISS' written request, ZEISS shall be free to develop competitive products on
its own or together with third parties. Nothing in this Agreement shall
constitute any right or license granted to ZEISS for the use of OEM
Developments, CELLOMICS Technology or Third Party OEM Developments or any
obligation to grant the same in the future. ZEISS may request such license at
any time in writing, the approval of which shall be solely with the discretion
of CELLOMICS. The term of the Exclusive Supply Period will be extended for an
additional one (1) year period if mutually agreed upon in writing by both
parties at least ninety (90) days prior to the expiration of the Exclusive
Supply Period or any extension thereof. Competitive products are not any
components or products for HTS.

         5.2 Exhibit 7.0 outlines the two year projections for ASK Workstations
and ASK Readers. After the first year of the Exclusive Supply Period, which
is defined to end on September 30, 2001, CELLOMICS and ZEISS will have a review
meeting in order to review purchase orders and delivery processes. By September
30th, 2001, a minimum purchase of [*] and [*] is required by CELLOMICS. In case
these quantities will not be met, either party hereto has the option of
terminating  the Exclusive Supply Period with ninety days prior written notice
to the other party.

     "CONFIDENTIAL [*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT
OF 1933, AS AMENDED."

                                      -11-

<PAGE>   12

                                   ARTICLE VI

                                     PRICING

         6.1 The parties agree that during calendar year 2000 the price at which
CELLOMICS may purchase ASK Readers shall be  [*]  and the price at which
CELLOMICS may purchase ASK Workstations shall be  [*]. Prices are further
detailed on Exhibit 8 which is attached hereto and made a part hereof.

         6.2 CELLOMICS agrees to supply ZEISS with a purchase forecast, on a
rolling six months basis, beginning March 1, 2000, of the number of ASK Readers
and ASK Workstations CELLOMICS intends to order in the quarter ended on the last
day of such six months.  [*]  With regard to subsequent orders, CELLOMICS
agrees to submit written purchase orders six (6) months prior to the expected
delivery date of ASK Readers and ASK Workstations. CELLOMICS understands that
prices set forth in paragraph 6.1 will be recalculated by ZEISS at the end of
the first year after Acceptance of the first ASK Workstation production unit and
each year thereafter. Recalculated prices will be limited to a maximum of 110%
of the previous year's price, with expectation that prices will actually be
reduced. Upon the purchase of twenty five ASK Workstations and fifteen ASK
Readers, the parties agree to negotiate

     "CONFIDENTIAL [*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT
OF 1933, AS AMENDED."

                                      -12-

<PAGE>   13

volume discounts in good faith. In the event the pricing as indicated in Section
6.1 is further reduced by at least  [*], CELLOMICS agrees to pay to ZEISS, as a
royalty,  [*]  of the reagent revenue derived from ASK Workstations and ASK
Readers during the initial Exclusive Supply Period. Upon renewal of the
Exclusive Supply Period the parties agree to negotiate in good faith discounts
and royalties. CELLOMICS shell submit to ZEISS a quarterly report on the value
of reagent sales derived from ASK Workstations and ASK Readers.

         6.3 ZEISS agrees to supply at least  [*]  and at least  [*]  during
the period  [*]  and following Acceptance of the first  [*]  ASK Workstation
series production units that the delivery time to CELLOMICS will not exceed
six (6) months after receipt of orders by ZEISS.

                                   ARTICLE VII

                                PRODUCT WARRANTY

         7.1 ZEISS warrants (1) that the ASK Reader and ASK Workstation
(sometimes herein referred to as Product or Products) will conform in all
material respects to CELLOMICS' specifications according to Exhibit 1.0 and 2.0;
(2) that CELLOMICS and/or the end user shall receive good and marketable title
to the Products upon shipment, free of any liens or claims; and (3) that the
Products will be free of defects in workmanship and materials for the lesser of
twelve (12) months after delivery to CELLOMICS or twelve (12) months after
purchase and opening of the Products by end-user customers. The

     "CONFIDENTIAL [*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT
OF 1933, AS AMENDED."

                                      -13-

<PAGE>   14

foregoing warranty shall not apply if the Products or component parts have been
subjected to abuse, misuse, accident or neglect. The aforementioned warranties
shall inure to CELLOMICS, its successors and assigns, and those who purchase or
use each Product from CELLOMICS.

         7.2 CELLOMICS will be responsible for providing Product support. For
any claim based on the foregoing warranties, CELLOMICS shall be responsible for
processing repairs or replacements. Defective Products shall be delivered to
ZEISS DDP (Incoterms 1990). ZEISS, at its option, will either repair or replace,
any defective Products with new or functionally equivalent and compatible parts
within thirty (30) days of receipt of said defective Product(s). ZEISS will
return the repaired Product or the replacement DDP (Incoterms 1990).
Alternatively, ZEISS agrees to provide end user warranty repairs at the request
of CELLOMICS. In this case, any costs incurring in processing end user warranty
repairs or replacements (except for replacement parts themselves) shall be
reimbursed by CELLOMICS to ZEISS. To facilitate their mutual responsibilities to
support the Products, the parties will agree to a minimum inventory of spare
parts to be purchased by CELLOMICS at discount prices negotiated between
CELLOMICS and ZEISS and which will be delivered to CELLOMICS by ZEISS no later
than August 15, 2000.

         7.3 The warranty provided in this Article VII shall be subject to
CELLOMICS' or the Products' end-user's satisfaction of the following conditions:
(1) a description of the failure of the Products alleged or found to be
defective shall be furnished to ZEISS in writing within a reasonable time of
discovery by CELLOMICS or the end-user of such

                                      -14-

<PAGE>   15

defect; (2) the defects so described shall be subject to ZEISS' reasonable
verification; (3) no Products alleged or found to be defective shall be disposed
of by CELLOMICS or the end-user for at least thirty (30) days after ZEISS
receives such description in writing; and (4) such defective Products or
applicable component(s) thereof shall forthwith be returned to ZEISS, freight
payable at destination, if ZEISS so requests.

         7.4 THIS LIMITED WARRANTY IS IN LIEU OF AND EXCLUDES ALL OTHER
WARRANTIES; EXPRESS OR IMPLIED; BY OPERATION OF LAW OR OTHERWISE, INCLUDING ANY
IMPLIED WARRANTY OF MERCHANTIBILITY OR FITNESS FOR A PARTICULAR PURPOSE: THE
SOLE AND EXCLUSIVE REMEDY AGAINST ZEISS WITH RESPECT TO ANY CLAIMED DEFECT IN
THE PRODUCT SHALL BE AS PROVIDED HEREIN AND SHALL IN NO CASE EXCEED THE COST OF
REPLACEMENT AND/OR REPAIR AT ZEISS' SITE IN JENA. ZEISS SHALL NOT BE LIABLE IN
CONTRACT OR IN TORT TO CELLOMICS OR ANY END USER OF THE PRODUCT FOR ANY SPECIAL
INCIDENTAL OR CONSEQUENTIAL DAMAGES WITH RESPECT TO THE PRODUCT OR WITH RESPECT
TO ZEISS' OBLIGATIONS WITH RESPECT TO THE PRODUCT SUCH AS, BUT NOT LIMITED TO
DAMAGE TO; LOSS OF OR LOSS OF THE USE OF OTHER PROPERTY OR EQUIPMENT, LOSS OF
PROFITS OR REVENUES OR CLAIMS OF CELLOMICS OR ANY END USER FOR LOSSES OF ANY
KIND, UNLESS CAUSED BY ZEISS' INTENT OR GROSS NEGLIGENCE.

ZEISS gives no warranty whatsoever with respect to parts with a limited
technical lifetime, such as, but not limited to bulbs and tubings. Components or
Products produced by other

                                      -15-

<PAGE>   16

manufacturers are warranted by ZEISS only to the extent that such are warranted
by the manufacturer supplying such components and to the extent that such
warranties may be assignable by ZEISS. ZEISS' warranty with respect to any
software included in the Products is limited to a warranty that such a software,
when properly installed, will not fail to execute its programming instructions
due to defects in materials and workmanship. If ZEISS receives notice of a
software defect during the applicable warranty period, ZEISS will replace
software media which do not execute programming instructions due to any defect.
ZEISS does not warrant that the operation of software will be uninterrupted or
error-free.

         7.5 CELLOMICS is providing a service organization capable of supporting
the Products at end users' sites. In order to be able to provide such support,
ZEISS will, at the request of CELLOMICS, offer training in Jena or in Pittsburgh
at CELLOMICS' cost. ZEISS will not charge any hourly rates for training and
traveling time.

         7.6 ZEISS will be able to supply spare parts or equivalent replacement
components for hardware and electronic components for ASK Reader or ASK
Workstation which are manufactured by ZEISS for five years after the end of
series production. With regard to third party components ZEISS agrees to use any
commercially reasonable efforts to maintain these third party components
operational for five years after end of series production of the ASK Reader and
the ASK Workstation. This may include replacement by other components providing
similar functions.

                                      -16-

<PAGE>   17

                                  ARTICLE VIII

                              TERM AND TERMINATION

         8.1 The parties agree that this Agreement supersedes, in its entirety,
the Former Agreement. The parties agree that the Agreement shall, unless sooner
terminated, continue in effect until December 31, 2005. Notwithstanding the
foregoing, the parties agree that the Agreement may be terminated by either
party on or after December 31, 2002 on not less than eighteen (18) months prior
written notice to the other. Upon notice by ZEISS to CELLOMICS that ZEISS
intends to terminate this Agreement, further payments of the Agreed Sum,
otherwise due pursuant to the terms of Paragraph 4.2 above, shall he canceled
and the unpaid balance of the Agreed Sum shall be forgiven.

         8.2 After termination, the parties agree to continue cooperating with
each other and to carry out an orderly termination of their relations.

         8.3 After termination of this Agreement, ZEISS shall cease to develop
or manufacture ASK Workstations and ASK Readers in any way, except ZEISS may
sell to CELLOMICS inventory on hand, and each party shall deliver to the other
all materials and documents belonging to the other which have come into its
possession as a result of this Agreement.

         8.4 For and during the eighteen (18) months following termination,
ZEISS shall offer to sell ZEISS components listed under ZEISS Technology on
Exhibit 4.0 to CELLOMICS, at such prices as would be proportional to the price
of such components had

                                      -17-

<PAGE>   18

such components been included in completed ASK Readers and ASK Workstations.
ZEISS will use commercially reasonable efforts to deliver all such ZEISS
components ordered by CELLOMICS within ninety (90) days of its receipt of any
such order.

         8.5 Notwithstanding anything to the contrary contained in this Article
VIII all the provisions of Paragraph 4.3 and Articles IX, X, XI, XII and XIII of
this Agreement shall continue in full force and effect after termination of this
Agreement for any reason.

                                   ARTICLE IX

               PATENTS, INVENTIONS AND ENFORCEMENT OF INTELLECTUAL

                                 PROPERTY RIGHTS

         9.1 Either party may, from time to time, discover potential or actual
infringers of the intellectual property of the other, or other proprietary
information of the other party which forms the basis of this Agreement. The
party discovering such infringement shall promptly inform the other of such
activity in writing. The party owning such intellectual property or proprietary
information shall take such steps as are, in such party's discretion,
economically feasible in order to enforce its ownership rights against the
infringer. Should ZEISS fail to enforce its ownership rights against the
infringers within a reasonable time, CELLOMICS shall have an independent right
of enforcement of these rights. In that event, CELLOMICS shall name ZEISS as a
party to such enforcement, and shall have sole discretion as to the action taken
against such potential or actual infringers, including, but not limited to the
identification of counsel and the settlement of all claims without

                                      -18-

<PAGE>   19

consultation with ZEISS. ZEISS shall also provide any or all reasonable
assistance to CELLOMICS, as deemed necessary by CELLOMICS or its counsel.

         9.2 Each party to this Agreement owning intellectual property hereby
agrees to indemnify the other party and to hold it harmless against any claim of
infringement from third parties with respect to any intellectual property
claimed to be owned by the owner party and used by the other party in the
performance of this Agreement, provided that the using party notifies the owner
party, in writing, on a timely basis, of any such claim of infringement, and
provided that the owner party stall have the control of the defense against any
such claim at its own expense, and provided, further, that no compromise thereof
shall be entered into without consent of the owner party.

         9.3 The parties agree that they will, by their officers, employees,
legal representatives or other persons duly authorized, communicate promptly to
each other or the representatives thereof, all facts known to them respecting
the products and services contemplated by this Agreement, or any other
proprietary information concerning the same, and will, upon request, testify in
any legal proceedings, sign all lawful papers, make all rightful oaths, and
generally do all other and further lawful acts, deemed necessary or expedient by
the other party or its counsel, to assist or enable that party to obtain and
enforce full benefits of this Agreement and the business relationship between
the parties.

         9.4 Each of the parties shall render its full cooperation to the other
in fulfilling and performing the terms of this Agreement.

                                      -19-

<PAGE>   20

         9.5 Neither party will hire personnel employed by the other party for a
period of twelve (12) months after the personnel in question has left employ of
the other party. The undertakings of this Article shall survive the termination
or expiration of this Agreement for twelve (12) months.

                                    ARTICLE X

                                 CONFIDENTIALITY

         10.1 Before and during the term of this Agreement, the parties will
disclose to each other certain confidential or proprietary information
("INFORMATION"), the disclosure of which to third parties could be commercially
injurious to the owner of the INFORMATION.

         10.2 The disclosure of the INFORMATION is solely for the purpose of the
furtherance of the development, marketing and sale of the contemplated products
and services described herein.

         10.3 Each party understands that the disclosing party considers the
INFORMATION to be confidential and a trade secret.

         10.4 Each party will not disclose to any third party, or utilize for
its own or another's benefit, the INFORMATION obtained from the disclosing
party.

                                      -20-

<PAGE>   21

         10.5 The term "INFORMATION" shall not include, and the parties shall
not have any obligations of confidence or non-disclosure with respect to:

         A. information that is in the public domain at the time of its
         transmittal or which subsequently comes into the public domain without
         violation of any obligation of confidence assumed hereunder;

         B. information received from a third party without violation of an
         obligation of confidence to the transmitting party; or

         C. information which the recipient party can show to have been in its
         possession at the time of transmittal; or

         D. information which the recipient party can show to have been
         independently developed by employees of the recipient party who have
         not had access to proprietary information received hereunder; or

         E. information which the recipient party is compelled to disclose
         pursuant to judicial action or the legal and enforceable request of a
         U.S. government agency, provided that the transmitting party is
         notified at the time such action or request is initiated, and further
         provided that the recipient party cooperates with the

                                      -21-

<PAGE>   22

         transmitting party in the event that the transmitting party seeks a
         protective order or other appropriate remedy to prevent disclosure of
         such information.

         10.6 If either party believes it essential to disclose any INFORMATION
to a third party, the party wishing to disclose will first advise the other
party what INFORMATION is to be disclosed, to whom it is to be disclosed and the
purpose therefor. The party wishing to disclose will first obtain the other
party's written permission to make the disclosure before making such disclosure,
which permission may not be unreasonably withheld. The requesting party also
agrees to require the third party recipient of the INFORMATION to acknowledge
that such INFORMATION is confidential, to hold the INFORMATION confidential for
the benefit of the disclosing party, and to sign a copy of a protective
agreement, naming the disclosing party as a third-party beneficiary having the
right to enforce the Agreement against the third party.

         10.7 All INFORMATION, where possible, shall be transferred from each
party to the other in written form, and shall bear a conspicuous mark
designating such INFORMATION to be confidential. Additionally, any INFORMATION
transferred from each party to the other in an oral or other non-permanent or
non-readable form, such as in a computer communication, shall be summarized in a
brief memorandum which shall also bear a conspicuous mark designating such
INFORMATION to be confidential. Furthermore, all INFORMATION transferred in
tangible form shall be returned to the disclosing party upon request and/or at
the termination of this Agreement.

                                      -22-

<PAGE>   23

         10.8 It is understood that this Agreement will neither obligate either
party, nor grant to either party or any employees, partners or other business
associate thereof, any rights in the INFORMATION, or any protectable interest
stemming therefrom, except as specifically provided herein.

         10.9 Each party agrees that if it or any of its employees, partners or
other business associates breaches any condition of this Agreement relating to
the protection of proprietary or confidential rights or information, the owner
of such right or information will be entitled to, in addition to all other
remedies available, an immediate injunction prohibiting the party in breach of
its obligations, or its employees, partners or other business associates, from
committing any further breach of the Agreement.

                                   ARTICLE XI

                           WARRANTIES AND DISCLAIMERS

         11.1 Each party represents and warrants to the other party that it has
no pre-existing contractual or other obligations to any third party which
preclude it from entering into this Agreement and meeting its obligations
hereunder, or which conflict with any provision of this Agreement.

         11.2 ZEISS warrants to CELLOMICS that the transfer price, as indicated
in Section 6.1 of ASK Workstation and ASK Reader does not include any research
and development costs.

                                      -23-

<PAGE>   24

         11.3 Each party represents and warrants to the other party that it
shall use reasonable efforts to achieve the objectives of the Agreement.

                                   ARTICLE XII

                    TRADEMARKS, SERVICE MARKS AND TRADE NAMES

         12.1 ZEISS Property

              The parties acknowledge that ZEISS has an exclusive and
proprietary right to its names and marks (hereafter the "ZEISS MARKS"). ZEISS
and CELLOMICS contemplate the use of some or all of the ZEISS MARKS in the
manufacture and sale of the products and services identified herein as indicated
by paragraph 2.3 hereof. Nothing in this Agreement shall be construed to grant
any right or license in and to the ZEISS MARKS to CELLOMICS except pursuant to
written licensure.

         12.2 CELLOMICS Property

              The parties acknowledge that CELLOMICS has an exclusive and
proprietary right to its names and marks including those identified in Exhibit
6.0 hereto (hereafter the "CELLOMICS MARKS"). CELLOMICS and ZEISS contemplate
the use of some or all of the CELLOMICS MARKS in the manufacture and sale of the
products and services identified herein. Nothing in this Agreement shall be
construed to grant any right or license in and to the CELLOMICS MARKS to ZEISS
except pursuant to written licensure.

                                      -24-

<PAGE>   25

                                  ARTICLE XIII

                                  MISCELLANEOUS

         13.1 Governing Law

              This Agreement shall be deemed made in Pittsburgh, Pennsylvania,
but shall be construed in accordance with the laws of the State of New York
applicable to contracts made and to be performed in New York. Notwithstanding
the foregoing, it is understood that no part of the performance by ZEISS of its
obligations under this Agreement shall take place in the United States, and
title to all personal property shipped to CELLOMICS or to end users shall pass
in the Federal Republic of Germany, and all risk of loss shall be borne by the
recipient of any such shipment following passage of title in Germany.

         13.2 Actions Survive

              All causes of action accruing to either party under this Agreement
shall survive termination for any reason, as shall provisions which expressly
state such survival unless such survival is conditional and the requisite
condition(s) has been fulfilled prior to or on such termination.

         13.3 Entire Agreement; Superseder; Section Headings, Construction

              This Agreement constitutes the only and entire understanding
between the parties concerning its subject matter and all other prior
negotiations, representations, agreements and understandings are superseded
hereby. No agreements altering or supplementing the terms hereof may be made
except by means of a written document signed by the duly

                                      -25-

<PAGE>   26

authorized representatives of the parties. The parties agree that this Agreement
supersedes, in its entirety, the Former Agreement.

The headings of Sections in this Agreement are provided for convenience only and
will not affect its construction or interpretation.

         13.4 Amendments

              This Agreement may be amended or modified only in writing, signed
by both parties.

         13.5 Independent Contractor

              Each party shall have the status of an independent contractor
without the authority to bind the other to any obligation.

         13.6 Arbitration

              All disputes which arise out of this Agreement shall be settled by
arbitration in Westchester County, New York in accordance with the conciliation
and arbitration rules and regulations of the American Arbitration Association,
to which the parties hereto submit including the AAA Optional Rules for
Emergency Measures of Protection to preserve the status quo ante of the parties.
The arbitrator shall have background and expertise relating to the issue(s)
involved. The arbitration shall be in English. The arbitration hearing shall be
held within sixty days of an arbitration demand. The arbitrator's decision shall
be submitted within thirty (30) days of the conclusion of the arbitration
hearing. The arbitrator's decision shall be binding, final and non-appealable.
The parties shall share

                                      -26-

<PAGE>   27

equally the cost of such arbitration. Any and all actions necessary to compel
arbitration or to enforce the decision of the arbitrator or any aspect thereof
shall be brought in the state or federal courts of Westchester County, New York
and the parties specifically agree that the state and federal courts of or
pertaining to Westchester County, New York shall have and the parties submit to
the exclusive jurisdiction and venue of such courts.

         13.7 Force Majeure

              If either party is prevented from performing any obligation
hereunder by reason of fire, explosion, strike, labor dispute, casualty,
accident, lack or failure of transportation facilities, flood, war, civil
commotion, acts of God, or any law, order or decree of any government or
subdivision thereof, then such party shall be excused from performance hereunder
to the extent and for the duration of such prevention, provided that such party
first notifies the other party in writing of such prevention.

         13.8 Publicity

              Except as required by law or applicable stock exchange rule, no
public statements shall be made by either party concerning this Agreement, its
subject matter or its existence without prior consultation with and the approval
of the other party, which approval shall not be unreasonably withheld. In the
event CELLOMICS undertakes an initial or subsequent public offering of its
stock, ZEISS agrees to review and give its approval to necessary statements
regarding the existence and/or subject matter of this Agreement within twenty
four (24) hours (but not less than one business day) of its receipt

                                      -27-

<PAGE>   28

of a draft of the proposed language regarding this Agreement and ZEISS shall not
unreasonably withhold such approval.

         13.9 Severability

               In the event that any provision of this Agreement shall be found
to be illegal, invalid or unenforceable for any reason, such shall not affect
the validity of the remainder of this Agreement, which shall be construed and
interpreted as though such provision was not present.

         13.10 Notices

               Notices may be given to an officer of a party by:

               A.  personal delivery,

               B.  fax

               C.  certified or registered mail addressed as follows:

               D.  overnight delivery by an internationally recognized courier
                   service

         All notices, demands, requests, consents, approvals and other
communications required or permitted hereunder must be in writing and will be
effective upon receipt if delivered personally to such party, or if sent by
facsimile transmission upon electronic confirmation of delivery, or if sent by
certified or registered mail upon receipt or if by internationally recognized
overnight courier service upon receipt at the address set forth below or at such
other address as any party may give to the other in writing for such purpose:

                                      -28-

<PAGE>   29

If to ZEISS:      Dr. Norbert Gorny         and          Dr. Robert Grub
                  Carl Zeiss Jena, GmbH                  Microscopy Division
                  Carl-Zeiss-Promenade 10                Carl Zeiss Jena, GmbH
                  07740 Jena, Germany                    07740 Jena, Germany

with a copy to:   Carl Zeiss Inc.
                  James Kelly
                  One Zeiss Drive
                  Thornwood, NY 10594

If to CELLOMICS:  D. Lansing Taylor, Ph.D.
                  President & Chief Executive Officer
                  635 William Pitt Way
                  Pittsburgh, PA 15238

with a copy to:   Sweeney Metz Fox McGrann & Schermer
                  The Westinghouse Building - 18th Floor
                  11 Stanwix Street
                  Pittsburgh, PA 15222

                                      -29-

<PAGE>   30

         13.11 Binding Effect

               This Agreement shall inure to the benefit of and be binding on
each party's successors in interest and assigns.

         13.12 Assignment

               Either party may assign this Agreement only in connection with
the sale or disposition of the entire business of such party or that portion to
which this Agreement pertains.

         IN WITNESS WHEREOF, this Agreement has been executed in multiple
counterparts, each of which shall constitute an original Agreement, on behalf of
the parties by their authorized officers as of the date first written above.

CARL ZEISS JENA GmbH

By I.V.                                           By I.V.
   -------------------------------------             ---------------------------

Its EVP                                           Its VP
   -------------------------------------             ---------------------------

Date  February 3, 2000                            Date February 3, 2000
    ------------------------------------              --------------------------

CELLOMICS, INC.

By /s/ D. LANSING TAYLOR
   -------------------------------------

Its President & CEO
   -------------------------------------

Date February 3, 2000
     -----------------------------------

                                      -30-
<PAGE>   31

                                  Exhibit 1.0

             Functional Requirements for the ArrayScan(TM) Kinetics
               Reader and Workstation for High Content Screening

(Pages 31-39)                          [*]

     "CONFIDENTIAL [*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT
OF 1933, AS AMENDED."

<PAGE>   32

                                  Exhibit 2.0

(Pages 1-36)                          [*]

     "CONFIDENTIAL [*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT
OF 1933, AS AMENDED."

<PAGE>   33

                                  Exhibit 3.0

(Page 1)                              [*]

     "CONFIDENTIAL [*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT
OF 1933, AS AMENDED."

<PAGE>   34

                                  Exhibit 4.0

(Pages 1-3)                            [*]

     "CONFIDENTIAL [*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT
OF 1933, AS AMENDED."

<PAGE>   35

                                  Exhibit 5.0

(Pages 1-49)                          [*]

     "CONFIDENTIAL [*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT
OF 1933, AS AMENDED."

<PAGE>   36

                                  Exhibit 6.0
                                  -----------

                                CELLOMICS MARKS

Cellomics' Trademarks
---------------------

[LOGO]

Cell Chip
ArrayScan
[*]
FluroTox
Cellomics
[*]
Cellective
[*]
Cell Explorer
HitKit
PharmacoCellomics
Vital Knowledge

     "CONFIDENTIAL [*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT
OF 1933, AS AMENDED."

<PAGE>   37

<TABLE>
<CAPTION>

         EXHIBIT 8.0: ASK PRICE LIST

No.      Component

<S>           <C>                                                <C>               <C>             <C>        <C>        <C>
1        Workstation
1.1      Chassis & enclosure workstation type 1                   [*]               [*]             [*]        [*]         [*]
         (USA)
1.2      Turntable Type 8                                         [*]               [*]             [*]        [*]         [*]
1.3      Turntable Type 9                                         [*]               [*]             [*]        [*]         [*]
1.4      Barcode scanner                                          [*]               [*]             [*]        [*]         [*]
1.5      Plate lift                                               [*]               [*]             [*]        [*]         [*]
1.6      Workstation software                                     [*]               [*]             [*]        [*]         [*]
1.7      System integration                                       [*]               [*]             [*]        [*]         [*]
1.8      CO2-Incubator 30 plates                                  [*]               [*]             [*]        [*]         [*]
1.9      Control PC with monitor                                  [*]               [*]             [*]        [*]         [*]
--------------------------------------------------------------

2
2.1      Liquid level detection for chemicals (7                  [*]               [*]             [*]        [*]         [*]
         sensors)
--------------------------------------------------------------

3
3.1      Interruption-free power supply [*]                       [*]               [*]             [*]        [*]         [*]
3.2      Battery box                                              [*]               [*]             [*]        [*]         [*]
3.3      Vacuum pump                                              [*]               [*]             [*]        [*]         [*]
3,4      COD Camera [*]                                           [*]               [*]             [*]        [*]         [*]
3,5      Controller Environmental Chamber                         [*]               [*]             [*]        [*]         [*]
3.6      Excitation filter [*]                                    [*]               [*]             [*]        [*]         [*]
3.7      Arc lamp HBO 200                                         [*]               [*]             [*]        [*]         [*]

3.8      Replacement lamp module HBO 200                          [*]               [*]             [*]        [*]         [*]

3.9      Liquid light guide HBO for ASK-Reader                    [*]               [*]             [*]        [*]         [*]

--------------------------------------------------------------

4
4.1      Pipetting Unit                                           [*]               [*]             [*]        [*]         [*]
4.2      ASK Redder                                               [*]               [*]             [*]        [*]         [*]
4.2.1    Housing/optics                                           [*]               [*]             [*]        [*]         [*]
4.2.2    Environmental chamber                                    [*]               [*]             [*]        [*]         [*]
4.2.3    Scanning table                                           [*]               [*]             [*]        [*]         [*]
--------------------------------------------------------------

5
5.1      Objective Plan-Neo 5x0.15                                [*]               [*]             [*]        [*]         [*]
5.2      Objective Plan-Neo 10x0.3                                [*]               [*]             [*]        [*]         [*]
5.3      Objective LD-Achroplan 20x0.40 Korr                      [*]               [*]             [*]        [*]         [*]
5.4      Objective LD-Aplan 40x0.50 Ph 2                          [*]               [*]             [*]        [*]         [*]
5.5      Objective Fluar 5x0.25                                   [*]               [*]             [*]        [*]         [*]
5.6      Objective Fluar 10x0.50                                  [*]               [*]             [*]        [*]         [*]
5.7      Objective Fluar 20x0.75UV                                [*]               [*]             [*]        [*]         [*]
5.8      Objective Plan-Neo 40x0.75                               [*]               [*]             [*]        [*]         [*]
5.9      AF-Controller                                            [*]               [*]             [*]        [*]         [*]
5.10     MOU 28 controller                                        [*]               [*]             [*]        [*]         [*]
5.11     Reflector cube                                           [*]               [*]             [*]        [*]         [*]
5.12     Fitter set 00 (green)                                    [*]               [*]             [*]        [*]         [*]
5.13     Filter set 02 (UV)                                       [*]               [*]             [*]        [*]         [*]
5.14     Filter set 09 (blue)                                     [*]               [*]             [*]        [*]         [*]
5.15     Filter set 26 (red)                                      [*]               [*]             [*]        [*]         [*]
--------------------------------------------------------------

==============================================================
         Array ScanKinetics
</TABLE>

     "CONFIDENTIAL [*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT
OF 1933, AS AMENDED."

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00018-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00018-of-00352.parquet"}]]